Business

Add as a preferred source on Google

Valeritas to Present and Participate in the Drug Delivery Technologies Panel at the Wedbush PacGrow Healthcare Conference

BRIDGEWATER, N.J., Aug. 01, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that John Timberlake, President and Chief Executive Officer, and Erick Lucera, Chief Financial Officer, are scheduled to present …

2 min read
EconoTimes — Reading the Times. Understanding the Future.

Read the original article

BRIDGEWATER, N.J., Aug. 01, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that John Timberlake, President and Chief Executive Officer, and Erick Lucera, Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference. The Company will also participate in the Drug Delivery Technologies Panel moderated in part by Tao Levy, Managing Director Medical Devices Equity Research. 

   
Event:  Wedbush Drug Delivery Technologies Panel
   
Date:  Tuesday, August 15, 2017
   
Time: 11:30 a.m. EDT
   
Location: New York, NY
   
   
Event:  Wedbush PacGrow Healthcare Conference Company Presentation
   
Date:  Wednesday, August 16, 2017
   
Time: 9:10 a.m. EDT
   
Location: New York, NY
   

An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.

About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Investor Contact:
Robert E. Flamm, Ph.D. / Brian Johnston
The Ruth Group
646-536-7017 / 7028
ir@valeritas.com

Or

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

Media Contact:
Kirsten Thomas / Cari Randall
The Ruth Group
508-280-6592 / 646-536-7002
pr@valeritas.com

Primary Logo

Related articles

View all